The European Interferon beta Pregnancy Registry
The European Interferon beta Pregnancy Registry represents the largest prospective cohort providing safety data on women with MS of childbearing age who have been exposed to any of the interferon beta therapies [1]. The registry included both spontaneous and solicited reports of pregnancies from patient support programs and Marketing Authorization Holder pharmacovigilance databases from 2009-2017.
The vast majority of known pregnancy outcomes of patients with exposure to interferon beta were live births without congenital anomalies [1]
Rates of spontaneous abortions and live births with congenital anomalies were consistent with those reported for the general population (spontaneous abortions: 10.7% vs 10-21%2; congenital anomalies: 2.1% vs 2.1-4.1% [3,4]) [1].
“Results from the registry showed no evidence that interferon beta exposure before conception and/or during early pregnancy increased the rate of congenital anomalies or spontaneous abortions, thus indicating that treatment with interferon beta may be continued until pregnancy is confirmed [1].”
References
- Hellwig K et al. J Neurol. 2020;267(6):1715-1723. Return to content
- Buss L et al. Acta Obstet Gynecol Scand 2006; 85(4): 467-75. Return to content
- Congenital Malformations Registry. New York State Department of Health, 2005. Return to content
- Zīle I et al. Cent Eur J Public Health 2014; 22(3): 147-52. Return to content
